Remdesevir Study

Ages Eligible for Study: Child, Adult, Older Adult
Sexes Eligible for Study: All

 

STAAMP Research will begin an outpatient treatment opportunity trial offering Remdesevir, a prodrug, to patients who have tested positive for the novel COVID-19 disease. This trial is free to the patients that participate and helps provide vital information to researchers as they continue to develop a treatment for current and emerging strains of the virus. An earlier study of the Remdesevir drug has shown that patients that receive the medication recovered up to four days faster than those patients who had not. Treatment intervention in the earlier phase of COVID-19 in an outpatient setting may prevent disease progression leading to hospitalization that would benefit patients and could reduce the burden on the healthcare system.

 

Leave a Reply

Your email address will not be published. Required fields are marked *